LEUKEMIC CD52 NEGATIVE GPI DEFECTIVE CLONES ARE COMMON IN ALL, ESCAPE ALEMTUZUMAB THERAPY, BUT ARE SENSITIVE TO RITUXIMAB MEDIATED COMPLEMENT DEPENDENT CYTOTOXICITY: RATIONALE FOR COMBINATION THERAPY
Author(s):
Nijmeijer, B.; Schie, M. van; Goselink, H.; Halkes, C.; Falkenburg, J.
